Discover
ABVX
Abivax S.A.
134.09
4 x 132.56
1 x 133.23
bid
ask
+
2.59
1.97%
24 @ 04:00 PM
132.66 -1.43 (1.07%)
| Ytd | -0.57% | |
| 1y | 1222.39% |
131.09
day range
134.74
9.96
52 week range
148.83
| Open | 131.78 | Prev Close | 131.50 | Low | 131.09 | High | 134.74 | Mkt Cap | 9.85B |
| Vol | 752.27K | Avg Vol | 2.06M | EPS | -1.91 | P/E | -70.29 | Forward P/E | -42.86 |
| Beta | 0.87 | Short Ratio | 1.15 | Inst. Own | 70.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-23 | 50-d Avg | 117.42 | 200-d Avg | 115.33 | 1yr Est | 161.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-09-14 | 2026-06 | -0.96 | N/A | N/A | N/A |
| 2026-05-22 | 2026-03 | -0.94 | -0.7 | 0.23 | 24.84% |
| 2026-03-23 | 2025-12 | -1.07 | -1.2 | -0.13 | -12.55% |
| 2025-09-08 | 2025-06 | -0.9 | -0.86 | 0.04 | 4.44% |
| 2025-03-24 | 2024-12 | -0.68 | -1.55 | -0.87 | -128.04% |
| 2024-11-07 | 2024-06 | -1.28 | -0.7 | 0.58 | 45.50% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-09 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-07-02 | Truist Securities | Upgrade | Buy | Buy |
| 2026-07-01 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-06-30 | Jefferies | Upgrade | Hold | Buy |
| 2026-06-30 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-06-30 | Wedbush | Upgrade | Neutral | Neutral |
Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | TCG Crossover Management, LLC | 6.48M | 0.00 | 8.12% |
| 2026-03-30 | UBS Group AG | 4.55M | 0.00 | 5.70% |
| 2026-03-30 | Darwin Global Management, Ltd. | 3.47M | 0.00 | 4.35% |
| 2026-03-30 | Morgan Stanley - Brokerage Accounts | 1.70M | 0.00 | 2.14% |
| 2026-03-30 | Vestal Point Capital LP | 1.50M | 0.00 | 1.88% |
| 2026-03-30 | Caligan Partners LP | 1.46M | 0.00 | 1.83% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Xtrackers MSCI World Swap ETF 1C | 760.11K | 0.00 | 0.95% |
| 2026-03-30 | Lord Abbett & Co. Growth Equity- SA | 468.49K | 0.00 | 0.59% |
| 2026-05-30 | Lord Abbett Growth Leaders I | 468.49K | 0.00 | 0.59% |
| 2026-03-30 | Lord Abbett Growth Leaders SMA | 468.49K | 0.00 | 0.59% |
| 2026-06-29 | iShares Biotechnology ETF | 463.62K | 0.00 | 0.58% |
| 2026-03-30 | Eventide Healthcare & Life Sciences I | 320.31K | 0.00 | 0.40% |